BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

...executive chairman and Joe Nolan as CEO, the former management team of AveXis partnered with Deerfield Management...
BioCentury | Feb 25, 2021
Deals

Feb. 24 Quick Takes: ICON buying PRA in $12B CRO deal; plus venture rounds for Yisheng, Xilio, Truvian, Lyvgen, AmacaThera, and more

...clinic this year. Rock Springs was joined by fellow new investors Bain Capital Life Sciences, Deerfield Management...
BioCentury | Feb 19, 2021
Emerging Company Profile

Frontier Medicines: tapping binding pockets across the proteome

...collaborators: UC BerkeleyCorporate partners: AbbVie Inc. (NYSE:ABBV)Number of employees: About 50Funds raised: $67 millionInvestors: MPM Capital, Deerfield Management...
BioCentury | Jan 29, 2021
Finance

Jan. 28 Quick Takes: Sana aims high in latest IPO prospectus; plus short interest in biotech, and fundings for Curevac, Design, Ukko, Encodia and more

...company Encodia raised a $75 million series C round, with lead investors Northpond Ventures and Deerfield Management...
BioCentury | Jan 27, 2021
Emerging Company Profile

Nuvalent: Structure-based design to address selectivity, tumor resistance

...two targeted programs for non-small cell lung cancer.Nuvalent Inc.’s emergence represents the latest evidence of Deerfield Management’s...
BioCentury | Jan 7, 2021
Finance

Werewolf’s conditionally-activated cancer therapies draw $72M series B, partnering interest

...roles at the Novartis Institutes for BioMedical Research (NIBR).Beyond RA Capital, Werewolf’s new series B investors include Deerfield Management...
BioCentury | Dec 22, 2020
Finance

Deerfield launches protein degradation start-up Neomorph with $109M series A

...series A round from founding investor Deerfield to advanced its targeted protein degradation platform and pipeline.Deerfield Management...
...with the Center for Protein Degradation, which Deerfield and Dana-Farber jointly launched in 2018. Virginia Li Neomorph Inc. Deerfield Management...
BioCentury | Oct 21, 2020
Deals

With roots in Medivation, Nuvation finds quick route to listing via year’s largest SPAC deal

...on Wednesday.Other investors in Nuvation’s PIPE include new investors 683 Capital, Ally Bridge, Avidity Partners, Deerfield Management...
BioCentury | Oct 21, 2020
Deals

Oct. 21 Quick Takes: Clear path for BMS in MyoKardia deal; plus WuXi Biologics rises, Purdue settles, Actemra, Cara-Vifor and more

...Innoviva Inc. affiliate and including existing investors Deerfield Management...
BioCentury | Oct 2, 2020
Finance

Next stop IPO? Olema adds to momentum with $85M series C

...well as expand its pipeline.New investors Avoro Capital Advisors, funds and accounts managed by BlackRock, Deerfield Management...
Items per page:
1 - 10 of 343
BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

...executive chairman and Joe Nolan as CEO, the former management team of AveXis partnered with Deerfield Management...
BioCentury | Feb 25, 2021
Deals

Feb. 24 Quick Takes: ICON buying PRA in $12B CRO deal; plus venture rounds for Yisheng, Xilio, Truvian, Lyvgen, AmacaThera, and more

...clinic this year. Rock Springs was joined by fellow new investors Bain Capital Life Sciences, Deerfield Management...
BioCentury | Feb 19, 2021
Emerging Company Profile

Frontier Medicines: tapping binding pockets across the proteome

...collaborators: UC BerkeleyCorporate partners: AbbVie Inc. (NYSE:ABBV)Number of employees: About 50Funds raised: $67 millionInvestors: MPM Capital, Deerfield Management...
BioCentury | Jan 29, 2021
Finance

Jan. 28 Quick Takes: Sana aims high in latest IPO prospectus; plus short interest in biotech, and fundings for Curevac, Design, Ukko, Encodia and more

...company Encodia raised a $75 million series C round, with lead investors Northpond Ventures and Deerfield Management...
BioCentury | Jan 27, 2021
Emerging Company Profile

Nuvalent: Structure-based design to address selectivity, tumor resistance

...two targeted programs for non-small cell lung cancer.Nuvalent Inc.’s emergence represents the latest evidence of Deerfield Management’s...
BioCentury | Jan 7, 2021
Finance

Werewolf’s conditionally-activated cancer therapies draw $72M series B, partnering interest

...roles at the Novartis Institutes for BioMedical Research (NIBR).Beyond RA Capital, Werewolf’s new series B investors include Deerfield Management...
BioCentury | Dec 22, 2020
Finance

Deerfield launches protein degradation start-up Neomorph with $109M series A

...series A round from founding investor Deerfield to advanced its targeted protein degradation platform and pipeline.Deerfield Management...
...with the Center for Protein Degradation, which Deerfield and Dana-Farber jointly launched in 2018. Virginia Li Neomorph Inc. Deerfield Management...
BioCentury | Oct 21, 2020
Deals

With roots in Medivation, Nuvation finds quick route to listing via year’s largest SPAC deal

...on Wednesday.Other investors in Nuvation’s PIPE include new investors 683 Capital, Ally Bridge, Avidity Partners, Deerfield Management...
BioCentury | Oct 21, 2020
Deals

Oct. 21 Quick Takes: Clear path for BMS in MyoKardia deal; plus WuXi Biologics rises, Purdue settles, Actemra, Cara-Vifor and more

...Innoviva Inc. affiliate and including existing investors Deerfield Management...
BioCentury | Oct 2, 2020
Finance

Next stop IPO? Olema adds to momentum with $85M series C

...well as expand its pipeline.New investors Avoro Capital Advisors, funds and accounts managed by BlackRock, Deerfield Management...
Items per page:
1 - 10 of 343